leisure time -WSS

leisure time

author：knowledge 2025-09-30 00:48:27 - browse：437

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： 2 US Navy sailors arrested for allegedly spying for China

WSS

Influencer to be charged after chaos erupts in New York City's Union Square

Americans' trust in science, scientist continues decline: Report

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Roche to buy Carmot Therapeutics, developer of obesity drugs

Pharma patents targeted by Biden in move to slash drug prices

Microsoft strikes partnership with Duke Health to advance health AI

explore

leisure time

explore

Duchenne breakthrough therapy leaves behind pioneering families

Patients' immediate access to test results puts radiologists in a bind

Cancer drug shortages should be causing more outrage

STAT letters to the editor on burnt

After affirmative action ruling, medical educators look to 'holistic review'

What Henrietta Lacks settlement says about racism in medicine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After sickle

Wildfire smoke exposes gaps in outdoor worker protections

Chemotherapy shortages won’t get better under Biden’s latest plan

Wikipedia

Humana, CVS hope to turn members into patients at clinics

Americans' trust in science, scientist continues decline: Report

STAT letters to the editor on burnt

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

FDA approves world's first CRISPR

Supreme Court wrestles with OxyContin maker's bankruptcy deal

explore

entertainment

Wikipedia

focus